The Cost-Effectiveness of Remdesivir for Hospitalized Patients With COVID-19

•The debate on how to assess the value of therapeutics for COVID-19 treatments continues as treatments (eg, remdesivir) gain regulatory approval and progress through clinical trials.•This article suggests the cost-effectiveness of remdesivir for hospitalized patients with COVID-19 and identifies key drivers of value to guide future pricing and reimbursement efforts.•With the current evidence available, remdesivir’s price is too high to align with its expected health gains. Results from this study provide a rationale for iterative health technology assessments in a pandemic.